Results 291 to 300 of about 26,970,723 (329)
Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation
Cyclin D1 overexpression altered the cell adhesion pathway, while cyclin D2 upregulation had less impact on pathway enrichment analysis. Multiple myeloma (MM) patients with cyclin D1 overexpression showed reduced CD56 expression and increased circulating tumor cells (CTC) levels, suggesting that cyclin D1 may contribute to MM cell dissemination ...
Ignacio J. Cardona‐Benavides+13 more
wiley +1 more source
Vol. 21: No. 2 (Spring 2016) Masthead [PDF]
Roger Williams University Law Review
core +1 more source
Small extracellular vesicles are a promising source of diagnostic molecules. We conducted a comprehensive study, including transcriptome profiling and RT‐qPCR validation on large cohorts of samples. Diagnostic panels enabling sensitive detection of colorectal cancer and precancerous lesions were established. Some molecules were differentially expressed
Petra Vychytilova‐Faltejskova+26 more
wiley +1 more source
How are patient partners involved in health service research? A scoping review of reviews. [PDF]
Tscherning SC+8 more
europepmc +1 more source
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza+3 more
wiley +1 more source
Dedication: Michael P. McNulty [PDF]
Roger Williams University Law Review Staff
core +1 more source
The Price Statistics of the Federal Goverment [PDF]
Price Statistics Review Committee
core +6 more sources
Robot-assisted technique versus freehand technique for spine surgery: an umbrella review. [PDF]
Li T, Yan J, Li J, Shang Y, Tang X.
europepmc +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source